Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGPLYGF 61 Debt-to-Equity is 0.38 as of Dec. 2025, which is 52% above its 10-year median of 0.25. GuruFocus rates PLYGF with a GF Score™ of 61/100 and a GF Value™ of $41.01 (Fairly Valued). The stock has 6 warning signs investors should review. Among 812 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 60.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PolyPeptide Group AG's Debt-to-Equity or its related term are showing as below:
PLYGF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.25 Max: 0.38
Current: 0.38
During the past 8 years, the highest Debt-to-Equity Ratio of PolyPeptide Group AG was 0.38. The lowest was 0.04. And the median was 0.25.
PLYGF's Debt-to-Equity is ranked worse than 60.1% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs PLYGF: 0.38
PolyPeptide Group AG (OTCPK:PLYGF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PolyPeptide Group AG Debt-to-Equity Related Terms
PolyPeptide Group AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLYGF vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a Debt-to-Equity of 0.38 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PolyPeptide Group AG and its competitors. This is 52% above median its historical median of 0.25. Over the past decade, PolyPeptide Group AG's Debt-to-Equity has ranged from 0.04 to 0.38. According to the industry distribution chart, PolyPeptide Group AG ranks #488 out of 812 companies in the Drug Manufacturers industry, placing it in the top 60.1%.
Is PolyPeptide Group AG's Debt-to-Equity too high?
PolyPeptide Group AG's current Debt-to-Equity of 0.38 is 52% above median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.38. The Drug Manufacturers industry median Debt-to-Equity is 0.27. PolyPeptide Group AG's value of 0.38 is 40.7% above this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #488 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #488 out of 812 companies for Debt-to-Equity. This places PolyPeptide Group AG in the lower half of its industry. The industry median Debt-to-Equity is 0.27. PolyPeptide Group AG's value of 0.38 is 40.7% above this benchmark. Historically, PolyPeptide Group AG's own Debt-to-Equity has ranged from 0.04 to 0.38 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.27, PolyPeptide Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Debt-to-Equity of 0.38 is 40.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Debt-to-Equity is 0.38, which is 52% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Fairly Valued. The stock's GF Value™ is $41.01, compared to a current price of $43.00 — trading 4.9% above its estimated fair value. The current Debt-to-Equity is 0.38, which is 52% above median its 10-year median of 0.25 and 40.7% above the Drug Manufacturers industry median of 0.27. PolyPeptide Group AG's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Debt-to-Equity is 0.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 4.9% above its estimated GF Value™ of $41.01.
GuruFocus considers PolyPeptide Group AG to be Fairly Valued.
Key valuation signals for PLYGF:
Debt-to-Equity: 0.38 (52% above median its 10-year median of 0.25)
GF Value™: $41.01 vs. price of $43.00 (4.9% above fair value)
Industry Position: 40.7% above the Drug Manufacturers median (#488 of 812)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
61GF Score
Get the complete analysis for PLYGF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
